A Real-world Wearables Study in Fabry Disease.
NCT06484478
Recruiting
Despite improvements in Fabry disease care in recent years, many patients still have poor outcomes. In addition to the many physical symptoms that patients can experience, the disease also places individuals at an increased risk of mental health conditions, such as anxiety and depression. Low physical activity levels and increased sedentary time are detrimentally associated with anxiety, depression and quality of life in the general population. Currently, no such research has been conducted in i... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/20/2024
Locations: Royal Free London NHS Foundation Trust, London, Not set
Conditions: Fabry Disease
Register for Updates
Cardio-Renal Registry
NCT06521801
Recruiting
Cardiovascular disease is the leading cause of morbidity and mortality among patients with chronic kidney disease (CKD). Even after adjustment for known cardiovascular risk factors, including diabetes and hypertension, mortality risk progressively increases with worsening CKD. As glomerular filtration rate (GFR) declines the probability of developing coronary artery disease (CAD) increases linearly, and patients with GFR \<60 mL/min/1.73 m2 have 2-3-fold increased CV mortality risk, relative to... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
12/20/2024
Locations: Barts Health NHS Trust, London, Not set
Conditions: End Stage Renal Disease, Cardio-Renal Syndrome, Myocardial Infarction, Cerebrovascular Accident, Percutaneous Coronary Intervention, Dialysis
Register for Updates
Chronic Radiation Induced Bowel Toxicity Study
NCT06640959
Recruiting
In the UK over 22,000 people undergo pelvic radiotherapy treatment per year, for several types of cancers including prostate cancer. The investigators want to investigate whether there are any differences in the bacteria in the bowel in patients with prostate cancer and whether these change during treatment. The aim of this study is to analyse the bacteria from the stool of patients undergoing radiotherapy for prostate cancer. The investigators will also look for any changes in the urine, blood... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Christie NHS Foundation Trust, Manchester, Greater Manchester +1 locations
Conditions: Prostate Cancer
Register for Updates
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
NCT02986516
Recruiting
Comparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/19/2024
Locations: Medical University of Graz, Graz, Not set +27 locations
Conditions: Chordoma
Register for Updates
EXTENDed Antibiotic Durations Compared to Standard Durations for Patients With Complicated Intra-abdominal Infection.
NCT05148702
Recruiting
A multicentre, open label, two-arm, parallel group, pragmatic, randomised controlled trial with internal pilot. A total of 1166 consenting adult patients with cIAI will be recruited and randomised on a 1:1 basis between 28-days antibiotics and standard care antibiotics. Patients will be followed up for 180 days to determine cost effectiveness and the rate of treatment failure in each group.
Gender:
ALL
Ages:
16 years and above
Trial Updated:
12/19/2024
Locations: Cwm Taf Morgannwg University Health Board,, Abercynon, Not set +35 locations
Conditions: Complicated Intra-abdominal Infection
Register for Updates
LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.
NCT06193902
Recruiting
This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Guy's and St Thomas' NHS Foundation Trust, London, Not set +1 locations
Conditions: Tumor, Solid
Register for Updates
Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
NCT06479135
Recruiting
This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxol... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/19/2024
Locations: Rocky Mountain Cancer Centers - Aurora, Aurora, Colorado +79 locations
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
Register for Updates
The Next Leap in Cardiac Magnetic Resonance Imaging:Cycling the Field
NCT04458883
Recruiting
The main aim of the study is to build and test a cardiac-specific coil purposely assembled in house to suit the FFC-MRI whole-body prototype and to test if it could be used for clinical cardiac scans in human subject populations.
Gender:
ALL
Ages:
20 years and above
Trial Updated:
12/18/2024
Locations: Cardiovascular Research Facility, Aberdeen, Aberdeenshire +1 locations
Conditions: Myocardial Infarction
Register for Updates
The EMBRACE Study The EMBRACE Study
NCT04467411
Recruiting
Cardiomyopathy is a condition that affects the heart muscle, whereby it becomes enlarged, thick or rigid. When the heart muscle becomes involved, it affects the pumping action of the heart. This condition can affect as many as 10% of all patients after undergoing anthracycline cancer drug therapy and unfortunately carries the worst prognosis of all cardiomyopathies. To date, there is no effective intervention that will prevent a patient from developing this condition. The research conducted will... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Cardiovascular Research Facility, Aberdeen, Aberdeenshire
Conditions: Breast Cancer
Register for Updates
Is There a Genetic Predisposition for Acute Stress-induced (Takotsubo) Cardiomyopathy
NCT04513054
Recruiting
Acute stress-induced (takotsubo) cardiomyopathy or broken heart syndrome presents like a heart attack, classically is triggered by intense emotional or physical stress and can have serious health consequences. In the current study the investigators wish to establish whether there is a genetic predisposition making certain people more susceptible to this condition. This could also have implications for their families.
Gender:
ALL
Ages:
All
Trial Updated:
12/18/2024
Locations: Cardiovascular Research Facility, Aberdeen, Aberdeenshire
Conditions: Takotsubo Cardiomyopathy
Register for Updates
An Evaluation of Remote Care (questionnaire+hybrid) in Patients Who Are Post-lung Transplant
NCT05916495
Recruiting
Lung transplantation is used to treat patients with lung damage when there is no other treatment option. Patients require close monitoring following their transplant, with hospital check-ups every 3-4 months usually lasting all day. Although check-ups often result in no change to patient management they are essential as patients have better outcomes if complications are detected quickly. The aim is to explore whether remote monitoring via an app (patientMpower) ± questionnaire (specifically des... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
12/18/2024
Locations: Manchester University NHS Foundation Trust, Manchester, Not set
Conditions: Lung Transplant; Complications
Register for Updates
A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma
NCT06071871
Recruiting
The PORTAL study will test a new combination of drugs (glofitamab, polatuzumab vedotin and obinutuzumab) in patients with large B-cell lymphoma (LBCL) that has come back (relapsed) or not responded to previous treatment. It will determine how safe and effective the combination of these cancer drugs is in treating LBCL before and after CAR-T cell therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/18/2024
Locations: Kings College Hospital NHS Foundation Trust, London, Not set +4 locations
Conditions: Large B-cell Lymphoma
Register for Updates